The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective

Over the past decade, the development of high-efficacy disease-modifying therapies (DMTs) has been responsible for more effective management of relapsing-remitting multiple sclerosis (RRMS). However, the gaps in optimal care for this complex disease remain. Alemtuzumab (Lemtrada®) is a highly effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Alroughani, Raed, Van Wijmeersch, Bart, Al Khaboori, Jabber, Alsharoqi, Isa Ahmed, Ahmed, Samar F., Hassan, Ali, Inshasi, Jihad, Krieger, Derk W., Shakra, Mustafa, Shatila, Ahmed Osman, Szolics, Miklos, Khallaf, Mohamed, Ezzat, Aly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498833/
https://www.ncbi.nlm.nih.gov/pubmed/32973927
http://dx.doi.org/10.1177/1756286420954119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498833/
https://www.ncbi.nlm.nih.gov/pubmed/32973927
http://dx.doi.org/10.1177/1756286420954119

Ejemplares similares